Literature DB >> 2319396

Prevalence and expression of familial combined hyperlipidemia in childhood.

J A Cortner1, P M Coates, P R Gallagher.   

Abstract

The objectives of this study were (1) to determine the incidence of dominantly inherited hyperlipoproteinemia in children referred to our medical center because of hyperlipidemia associated with a family history of premature coronary artery disease and (2) to assess the degree of expression in childhood of the most common inherited hyperlipoproteinemia, familial combined hyperlipidemia. Among 129 families referred to us by area pediatricians, we identified a dominantly inherited hyperlipoproteinemia in 97 of them. Twenty had familial hypercholesterolemia, 65 familial combined hyperlipidemia, 11 hyperapobetalipoproteinemia, and one familial hypertriglyceridemia. As expected, almost half (9/20) of the siblings of probands with familial hypercholesterolemia were affected. Although we expected incomplete gene penetrance in the siblings of the probands with familial combined hyperlipidemia, we found 43 affected and 40 unaffected among the 83 siblings of the 65 probands. Our findings suggest that hyperlipidemia in children, caused by familial combined hyperlipidemia, occurs more than three times as frequently as familial hypercholesterolemia and that in families identified by a child proband, the penetrance is complete. Pediatricians should identify this primary hyperlipidemia in childhood and attempt to prevent the associated risk of premature coronary artery disease by prescribing appropriate diet and life-style modifications.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2319396     DOI: 10.1016/s0022-3476(05)81595-1

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  10 in total

Review 1.  Role of lipid-lowering pharmacotherapy in children.

Authors:  S Tonstad
Journal:  Paediatr Drugs       Date:  2000 Jan-Feb       Impact factor: 3.022

2.  A young male with familial hypercholesterolemia.

Authors:  Afzalur Rahman; Moeen Uddin Ahmed; A K M Monwarul Islam; Aparajita Karim; Shafiqul A Sarker
Journal:  J Saudi Heart Assoc       Date:  2012-08-04

Review 3.  Treatment of dyslipidemia in children and adolescents.

Authors:  Kathryn Wood Holmes; Peter Oscar Kwiterovich
Journal:  Curr Cardiol Rep       Date:  2005-11       Impact factor: 2.931

4.  The effect of lovastatin on very low-density lipoprotein apolipoprotein B production by the liver in familial combined hyperlipidaemia.

Authors:  J A Cortner; M J Bennett; N A Le; P M Coates
Journal:  J Inherit Metab Dis       Date:  1993       Impact factor: 4.982

Review 5.  Pediatric lipid management: an earlier approach.

Authors:  Justin P Zachariah; Philip K Johnson
Journal:  Endocrinol Metab Clin North Am       Date:  2014-12       Impact factor: 4.741

6.  Drug therapy of hypercholesterolaemia in children and adolescents.

Authors:  Marjet J A M Braamskamp; Frits A Wijburg; Albert Wiegman
Journal:  Drugs       Date:  2012-04-16       Impact factor: 9.546

7.  Impaired fatty acid metabolism in familial combined hyperlipidemia. A mechanism associating hepatic apolipoprotein B overproduction and insulin resistance.

Authors:  M Castro Cabezas; T W de Bruin; H W de Valk; C C Shoulders; H Jansen; D Willem Erkelens
Journal:  J Clin Invest       Date:  1993-07       Impact factor: 14.808

8.  Familial combined hyperlipidaemia: use of stable isotopes to demonstrate overproduction of very low-density lipoprotein apolipoprotein B by the liver.

Authors:  J A Cortner; P M Coates; M J Bennett; D R Cryer; N A Le
Journal:  J Inherit Metab Dis       Date:  1991       Impact factor: 4.982

9.  Screening for hyperlipidaemia in childhood. Recommendations of the British Hyperlipidaemia Association.

Authors:  R Wray; H Neil; J Rees
Journal:  J R Coll Physicians Lond       Date:  1996 Mar-Apr

10.  Case Studies in Pediatric Lipid Disorders and Their Management.

Authors:  Ambika P Ashraf; Bhuvana Sunil; Vaneeta Bamba; Emily Breidbart; Preneet Cheema Brar; Stephanie Chung; Anshu Gupta; Aditi Khokhar; Seema Kumar; Marissa Lightbourne; Manmohan K Kamboj; Ryan S Miller; Nivedita Patni; Vandana Raman; Amy S Shah; Don P Wilson; Brenda Kohn
Journal:  J Clin Endocrinol Metab       Date:  2021-11-19       Impact factor: 6.134

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.